HealthDay - Clinical Trials Update: Nov. 26, 2007
By Jeff Swiatek, The Indianapolis Star Knight Ridder/Tribune Business News
Apr. 23–The Prozac blahs seem over for Eli Lilly and Co., which on Tuesday reported its highest sales jump since the patent on its famous antidepressant expired nearly two years ago.
Sales from January through March grew 13 percent, to $2.89 billion, over the same period a year ago, the drugmaker said Tuesday.
Most Popular
Today’s Best Part-Time Jobs
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
Top Ten Public Speaking Tips
5 Regular Mistakes In Public Speaking
Lilly’s No. 1 product, the antipsychotic Zyprexa, led the growth surge with a 17 percent jump in sales, despite the U.S. arrival of Abilify, a competing schizophrenia drug from Bristol-Myers …
Read the rest of this article with a Free Trial at HighBeam Research.
